<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329627</url>
  </required_header>
  <id_info>
    <org_study_id>NP 50/2010 - TAME</org_study_id>
    <nct_id>NCT01329627</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer</brief_title>
  <acronym>TAME-01</acronym>
  <official_title>Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação Faculdade de Medicina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether weekly paclitaxel followed by weekly&#xD;
      doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor&#xD;
      (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Toxicity&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>18 weeks</time_frame>
    <description>Incidence of febrile neutropenia with modified metronomic schedule (whithout GCSF) will be no higher than 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>From the beginning of treatment until surgery, progression and death</time_frame>
    <description>Efficacy will be assessed by:&#xD;
Tumor measurements using MRI&#xD;
Pathologic complete response&#xD;
Progression-free survival&#xD;
Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Locally Advanced HER2-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel/doxorubicin/cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/doxorubicin/cyclophosphamide</intervention_name>
    <description>Metronomic chemotherapy as described below:&#xD;
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;&#xD;
Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.</description>
    <arm_group_label>Paclitaxel/doxorubicin/cyclophosphamide</arm_group_label>
    <other_name>Metronomic chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/doxorubicin/cyclophosphamide</intervention_name>
    <description>Metronomic chemotherapy as described below:&#xD;
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.</description>
    <arm_group_label>Paclitaxel/doxorubicin/cyclophosphamide</arm_group_label>
    <other_name>Metronomic chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced breast cancer diagnosed by guided core biopsy&#xD;
&#xD;
          -  T &gt; 2 cm (any N), or any T and node positive (needle biopsy is required)&#xD;
&#xD;
          -  Non-metastatic disease assessed by computed tomography and bone scintigraphy&#xD;
&#xD;
          -  Histological grade 2 and Ki67 &gt; 15% or&#xD;
&#xD;
          -  Histological grade 3 or&#xD;
&#xD;
          -  Any triple negative (TN) or&#xD;
&#xD;
          -  Inflammatory breast cancer (IBC)&#xD;
&#xD;
          -  Normal left ventricular ejection fraction (LVEF)&#xD;
&#xD;
          -  HER2-negative disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another malignancy within the last 5 years (except curatively treated skin carcinoma,&#xD;
             in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular&#xD;
             carcinoma of the breast)&#xD;
&#xD;
          -  Clinically significant comorbidities as cardiovascular diseases, chronic obstructive&#xD;
             pulmonary disease (COPD), renal or liver failure, psychiatric disorders&#xD;
&#xD;
          -  LVEF value below institutional limits of normal&#xD;
&#xD;
          -  Predominant lobular carcinoma histology&#xD;
&#xD;
          -  Grade 1 tumors&#xD;
&#xD;
          -  Detected or suspicious distant metastasis&#xD;
&#xD;
          -  Neutrophils less than 1,500/µL, platelets less than 100,000/µL, hemoglobin less than&#xD;
             10 g/dL, AST more than 2.5x upper limit of normal (ULN), total bilirubin more than&#xD;
             ULN, alkaline phosphatase more than 1.5x ULN&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  HER2-positive breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State of Sao Paulo Cancer Institute</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

